Genotype distributions of polymorphisms in studies included in the current meta-analysis
| No. of patients with good response (%) | Total no. of patients | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gene | Polymorphism | Study group (year) | Definition of a good response | 1* | 2* | 3* | 1* | 2* | 3* |
| VEGF-A | Rs699947 A>C | Hautam'a'ki (2013) | Retinal exudate resolved(measured by OCT) | 17 (51.5) | 19 (40.4) | 8 (50.0) | 33 | 47 | 16 |
| Kitchens (2013) | Retinal exudate resolved(measured by OCT) | 6 (24.0) | 11 (20.4) | 3 (15.0) | 25 | 54 | 20 | ||
| Lazzeri (2013) | Retinal exudate resolved(measured by OCT) | 3 (33.3) | 17 (54.8) | 14 (58.3) | 9 | 31 | 24 | ||
| Park (2014) | Gain of ≥5 letters | 21 (75.0) | 50 (42.4) | 62 (50.0) | 28 | 118 | 124 | ||
| Hagstrom (2014) | Gain of ≥5 letters | 60 (29.9) | 126 (30.8) | 65 (28.9) | 201 | 409 | 225 | ||
| Retinal exudate resolved(measured by OCT) | 44 (21.9) | 137 (33.5) | 58 (25.8) | ||||||
| Cruz-Gonzalez (2014) | Gain of ≥5 letters | 11 (68.8) | 20 (43.5) | 15 (46.9) | 16 | 46 | 32 | ||
| Retinal exudate resolved(measured by OCT) | 12 (75.0) | 30 (65.2) | 18 (56.3) | ||||||
| Van Asten (2014) | Loss of VA<30% of letters | 98 (29.6) | 158 (47.7) | 75 (22.7) | 113 | 179 | 83 | ||
| Rs 699946 A>G | Park (2014) | Gain of ≥5 letters | 45 (47.9) | 67 (51.1) | 24 (50.0) | 94 | 131 | 48 | |
| Hagstrom (2014) | Gain of ≥5 letters | 167 (31.2) | 78 (29.0) | 6 (19.4) | 535 | 269 | 31 | ||
| Retinal exudate resolved(measured by OCT) | 150 (28.0) | 78 (29.0) | 11 (35.5) | ||||||
| Rs 833069 C>T | Hagstrom (2014) | Gain of ≥5 letters | 29 (28.2) | 111 (30.9) | 111 (29.8) | 103 | 359 | 373 | |
| Retinal exudate resolved(measured by OCT) | 23 (22.3) | 114 (31.8) | 102 (27.3) | ||||||
| Van Asten (2014) | Loss of VA<30% of letters | 45 (13.8) | 137 (42.2) | 143 (44.0) | 52 | 158 | 158 | ||
| Rs 833061 C>T | Kitchens (2013) | Retinal exudate resolved(measured by OCT) | 3 (15.0) | 11 (20.4) | 6 (24.0) | 20 | 54 | 25 | |
| Park (2014) | Gain of ≥5 letters | 21 (75.0) | 53 (43.8) | 62 (50.8) | 28 | 121 | 122 | ||
| Cruz-Gonzalez (2014) | Gain of ≥5 letters | 14 (70.0) | 19 (41.3) | 13 (50.0) | 20 | 46 | 28 | ||
| Retinal exudate resolved(measured by OCT) | 16 (80.0) | 28 (60.9) | 16 (57.1) | ||||||
| Rs 2146323 A>C | Hautam'a'ki (2013) | Retinal exudate resolved(measured by OCT) | 8 (57.1) | 20 (43.5) | 16 (44.4) | 14 | 46 | 36 | |
| Hagstrom (2014) | Gain of ≥5 letters | 27 (27.8) | 120 (31.8) | 104 (28.8) | 97 | 377 | 361 | ||
| Retinal exudate resolved(measured by OCT) | 23 (23.7) | 113 (30.0) | 103 (28.5) | ||||||
| Rs 1413711 T>C | McKibbin (2012) | Gain of ≥5 letters | 10 (40.0) | 29 (55.8) | 14 (51.9) | 25 | 52 | 27 | |
| Hagstrom (2014) | Gain of ≥5 letters | 62 (30.0) | 122 (30.1) | 67 (29.1) | 207 | 398 | 230 | ||
| Retinal exudate resolved(measured by OCT) | 48 (23.2) | 130 (32.7) | 61 (26.2) | ||||||
| Rs 2010963 C>G | Kitchens (2013) | Retinal exudate resolved(measured by OCT) | 9 (20.0) | 10 (23.3) | 1 (9.0) | 45 | 43 | 11 | |
| Hagstrom (2014) | Gain of ≥5 letters | 28 (28.3) | 112 (31.0) | 111 (29.6) | 99 | 361 | 375 | ||
| Retinal exudate resolved(measured by OCT) | 23 (23.2) | 112 (31.0) | 104 (27.7) | ||||||
| Rs1570360 A>G | Kitchens(2013) | Retinal exudate resolved(measured by OCT) | 1 (8.3) | 9 (20.0) | 10 (23.8) | 12 | 45 | 42 | |
| Lazzeri (2013) | Retinal exudate resolved(measured by OCT) | 23 (71.9) | 13 (50.0) | 1 (16.7) | 32 | 26 | 6 | ||
| VEGFR 2 | Rs 2071559 A>G | Hagstrom (2014) | Gain of ≥5 letters | 59 (30.6) | 128 (30.9) | 64 (28.1) | 193 | 414 | 228 |
| Retinal exudate resolved(measured by OCT) | 58 (30.0) | 108 (26.0) | 73 (32.0) | ||||||
| Cruz-Gonzalez (2014) | Gain of ≥5 letters | 7 (43.8) | 25 (53.2) | 14 (45.2) | 16 | 47 | 31 | ||
| Retinal exudate resolved(measured by OCT) | 10 (62.5) | 33 (70.2) | 17 (54.8) | ||||||
Bold text highlights positive results.
1*, Homozygous wild type; 2*, Heterozygous variant; 3*, Homozygous variant; OCT, optical coherence tomography; VA, visual acuity; VEGF-A, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor.